Safety of Semaglutide After Dialysis Initiation: An Individual-Level Pooled Analysis
Authors' conclusion
Although more evidence is needed, continuation of semaglutide after dialysis initiation appears safe and warrants efficacy testing regarding reduction in MACE and death.
Study context
- Population
- Trial participants (with T2D, or without T2D with obesity and high cardiovascular risk) who initiated dialysis during follow-up and remained on treatment307 initiated dialysis
- Participants
- 165 participants
- Comparison
- Semaglutide vs placebo, continued after dialysis initiation
- Semaglutiden = 71
- Placebon = 94reference
- Outcome
- Systematically collected serious adverse events (AEs) (serious AEs (SAEs)), including adjudicated major adverse cardiovascular events (MACE), after dialysis initiation
Methodological detailsplacebo-controlled, pooled analysis of SUSTAIN-6, SELECT, FLOW and SOUL
- Placebo-controlled
- Pooled analysis of SUSTAIN-6, SELECT, FLOW and SOUL
Pooled result
As reported in the abstract
SAEs after dialysis initiation
Further pooled results
Events per 100 person-years
| Outcome | Semaglutide | Placebo |
|---|---|---|
| MACE event rate | 9.7 | 16.1 |
| All-cause mortality event rate | 13.8 | 18.1 |
Safety
Permanent discontinuation of trial medication
Original publication
Safety of Semaglutide After Dialysis Initiation: An Individual-Level Pooled Analysis. Diabetes Care. Published 27 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →